Clinical Trial Update: HDAC Inhibitor Augmentation to Clozapine [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating HDAC inhibitor augmentation to Clozapine for schizophrenia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Clozapine (Clozapine)
• HDAC inhibitor (unspecified)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Schizophrenia | EARLY_Phase 1 | Status: WITHDRAWN